System Certification ISO 9001:2000
Exbio Antibodies CZ / SK eShop
by categories | a-z list | Application type: Flow Cytometry | Immunohistochemistry | Functional Studies

Mouse Monoclonal to CD134

Ber-ACT35 (IgG1)

Technical Information Request    Inquiry for Bulk Prices

Product No. Form Quantity Stock Price Datasheet Shop
  11-152-C025 purified 0.025 mg yes choose region PDF datasheetHTML datasheet buy
  11-152-C100 purified 0.1 mg yes choose region PDF datasheetHTML datasheet buy
  1F-152-T100 FITC 100 tests yes choose region PDF datasheetHTML datasheet buy
  1P-152-T025 PE 25 tests yes choose region PDF datasheetHTML datasheet buy
  1P-152-T100 PE 100 tests yes choose region PDF datasheetHTML datasheet buy
  1A-152-T100 APC 100 tests yes choose region PDF datasheetHTML datasheet buy
- In stock! Ready for immediate despatch - Manufacture on order


CD134 (TNFRSF4, also known as OX40) is a type I transmembrane glycoprotein of TNF/NGF receptor family expressed on activated T cells, fibroblasts, and hematopoietic precursors. Binding to its ligand (OX40L, TNFSF4) on antigen presenting cells gives to the T cell costimulatory signal, and this interaction results also in B cell proliferation and influences T cell memory pool. CD134 is upregulated at sites of inflammation, especially in case of multiple sclerosis and psoriatic lesions.


The mouse monoclonal antibody Ber-ACT35 (also known as ACT35) recognizes CD134 (TNFRSF4, OX40), an approximately 50 kDa type I transmembrane glycoprotein expressed on activated T cells.
HLDA VI: WS Code C-31

Regulatory Status


HTLV 1-transformed HUT-102 cells

Species Reactivity:

  • Human
  • Non-Human Primates

Negative Species:


  • Flow Cytometry
  • Immunoprecipitation
  • Western Blotting
  • Immunohistochemistry (paraffin sections)
  • Immunohistochemistry (frozen sections)
Usage note:
Indicated dilutions are recommended starting points for use of this product. Working concentrations should be determined by the investigator.

Product Specific References

  • *Tanijiri T, Shimizu T, Uehira K, Yokoi T, Amuro H, Sugimoto H, Torii Y, Tajima K, Ito T, Amakawa R, Fukuhara S: Hodgkin's reed-sternberg cell line (KM-H2) promotes a bidirectional differentiation of CD4+CD25+Foxp3+ T cells and CD4+ cytotoxic T lymphocytes from CD4+ naive T cells. J Leukoc Biol. 2007 Sep;82(3):576-84. [Abstract] [Full Text]
  • *Willett BJ, McMonagle EL, Ridha S, Hosie MJ: Differential utilization of CD134 as a functional receptor by diverse strains of feline immunodeficiency virus. J Virol. 2006 Apr;80(7):3386-94. [Abstract]
  • *Li M, Zhang Y: The effect of anti-human CD134 monoclonal antibody on phytohemagglutinin-induced mRNA expression of perforin in peripheral blood mononuclear cells. Cell Mol Immunol. 2005 Dec;2(6):467-71. [Abstract]
  • *Voo KS, Bover L, Harline ML, Vien LT, Facchinetti V, Arima K, Kwak LW, Liu YJ: Antibodies targeting human OX40 expand effector T cells and block inducible and natural regulatory T cell function. J Immunol. 2013 Oct 1;191(7):3641-50. [Abstract]
  • *Endl J, Rosinger S, Schwarz B, Friedrich SO, Rothe G, Karges W, Schlosser M, Eiermann T, Schendel DJ, Boehm BO: Coexpression of CD25 and OX40 (CD134) receptors delineates autoreactive T-cells in type 1 diabetes. Diabetes. 2006 Jan;55(1):50-60. [Abstract] [Full Text]
  • *Aten J, Roos A, Claessen N, Schilder-Tol EJ, Ten Berge IJ, Weening JJ: Strong and selective glomerular localization of CD134 ligand and TNF receptor-1 in proliferative lupus nephritis. J Am Soc Nephrol. 2000 Aug;11(8):1426-38. [Abstract] [Full Text]
  • *Jones D, Fletcher CD, Pulford K, Shahsafaei A, Dorfman DM: The T-cell activation markers CD30 and OX40/CD134 are expressed in nonoverlapping subsets of peripheral T-cell lymphoma. Blood. 1999 May 15;93(10):3487-93. [Abstract]
  • For research use only. Not for drug, diagnostic or other use.

    Example Data

    Fig. 1

    Fig. 1. Surface staining of human PHA-activated leukocytes with anti-human CD134 (Ber-ACT35) purified, GAM APC.

    Ber-ACT35 PE

    Fig. 2. Surface staining of human PMA + ionomycin activated PBMC with anti-human CD134 (Ber-ACT35) PE.

    Unless indicated otherwise, all products are For Research Use Only and not for diagnostic or therapeutic use. Not for resale or transfer either as a stand-alone product or as a component of another product without written consent of EXBIO. EXBIO will not be held responsible for patent infringement or other violations that may occur with the use of our products. All orders are accepted subject to EXBIO´s term and conditions which are available at
    © 2003 EXBIO. All rights reserved.
    terms and conditions | privacy policy